A robust high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS) assay was developed and qualified for the measurement of cyclic nucleotides (cNTs) in rat brain tissue. Stable isotopically labeled 3 ,5 -cyclic adenosine-13 C 5 monophosphate ( 13 C 5 -cAMP) and 3 ,5 -cyclic guanosine-13 C, 15 N 2 monophosphate ( 13 C 15 N 2 -cGMP) were used as surrogate analytes to measure endogenous 3 ,5 -cyclic adenosine monophosphate (cAMP) and 3 ,5 -cyclic guanosine monophosphate (cGMP). Preweighed frozen rat brain samples were rapidly homogenized in 0.4 M perchloric acid at a ratio of 1:4 (w/v). Following internal standard addition and dilution, the resulting extracts were analyzed using negative ion mode electrospray ionization LC-MS/MS. The calibration curves for both analytes ranged from 5 to 2000 ng/g and showed excellent linearity (r 2 > 0.996). Relative surrogate analyte-to-analyte LC-MS/MS responses were determined to correct concentrations derived from the surrogate curves. The intra-run precision (CV%) for 13 C 5 -cAMP and 13 C 15 N 2 -cGMP was below 6.6% and 7.4%, respectively, while the inter-run precision (CV%) was 8.5% and 5.8%, respectively. The intra-run accuracy (Dev%) for 13 C 5 -cAMP and 13 C 15 N 2 -cGMP was <11.9% and 10.3%, respectively, and the inter-run Dev% was <6.8% and 5.5%, respectively. Qualification experiments demonstrated high analyte recoveries, minimal matrix effects and low autosampler carryover. Acceptable frozen storage, freeze/thaw, benchtop, processed sample and autosampler stability were shown in brain sample homogenates as well as post-processed samples. The method was found to be suitable for the analysis of rat brain tissue cAMP and cGMP levels in preclinical biomarker development studies.
Introduction
3 ,5 -cyclic adenosine monophosphate (cAMP) and 3 ,5 -cyclic guanosine monophosphate (cGMP) are important second messengers for signaling in a wide variety of cellular pathways [1] . These cyclic nucleotides (cNTs) are synthesized by adenylyl or guanosine cyclases and removed from the cell through efflux, such as multidrug resistance-associated protein 4 (MRP4) [2] , or degraded by phosphodiesterases (PDEs). Clinically, decreased cNT levels in cerebrospinal fluid have been associated with Alzheimer's disease, schizophrenia, Creutzfeldt-Jakob Disease and other neu-rodegenerative diseases [3] [4] [5] [6] [7] [8] . Accordingly, therapies targeting these indications are intended to increase local cNT levels. Indeed, inhibition PDEs, enzymes which inactivate cNTs, have been evaluated as a target for many therapeutic areas including pulmonary disease, skin disorders and especially CNS disorders including cognition and memory impairment [9] [10] [11] [12] [13] . The modulation of cAMP and/or cGMP in rodent tissues including brain has been proposed as a preclinical biomarker for certain disease models as well as an indicator of phosphodiesterase (PDE) inhibition [14, 15] .
Since their discovery five decades ago, the analysis of cNTs has evolved from complex chromatography based approaches or radio immunoassays [16] [17] [18] to more specific enzyme-linked immunosorbent assay (ELISA) or liquid chromatography/tandem mass spectrometry (LC-MS/MS) based analysis [19] [20] [21] . ELISA has been commonly used to quantify cyclic nucleotides due to its high sensitivity, however, matrix interference can result in low precision and accuracy when measuring cNTs in complex biological matrices. ELISA is further limited by its ability to only measure one cNT at a time thereby adding cost and lowering throughput. These drawbacks can be resolved with the application of LC-MS/MS which provides a means to simultaneously analyze both cAMP and cGMP in complex matrices and is therefore more economical [14, 21] . Although LC-MS/MS is less sensitive than ELISA, the sub-nanomolar sensitivity that can be achieved with LC-MS/MS is nonetheless adequate for the analysis of endogenous cNTs present in typical rat brain, CSF and plasma samples. One of the major advantages of the LC-MS/MS method is its potential for very high selectivity, as well as the ability to analyze multiple analytes, including drug substances, in a single run.
For accurate quantification using LC-MS/MS, the calibration curve should be prepared in an analyte-free matrix. However, this is not possible when directly analyzing endogenous analytes such as cAMP or cGMP. Some investigators have produced cNT-free matrix (plasma) by aging it at room temperature until the cNTs were degraded [21] . This approach was deemed impractical for rat brain tissue since the cAMP and cGMP levels are significantly higher than those in the plasma and it may take a long time to completely degrade cNTs at room temperature. In addition, the process of aging the brain tissue may cause matrix differences in the calibration curve compared to study samples that cannot be treated in this way. Therefore alternative quantification approaches such as standard addition, surrogate analyte, surrogate matrix and background subtraction [22, 23] were considered. Of these approaches, the use of stable isotope labeled standards as surrogate analytes to allow calibration in the actual biological matrix has been shown to be an attractive approach [24, 25] . Here, we report the first application of the surrogate analyte approach for analysis of cAMP and cGMP in rat brain tissue. In this study, we developed a LC-MS/MS bioanalytical method using 3 ,5 -cyclic adenosine-13 C 5 monophosphate ( 13 C 5 -cAMP) as a surrogate analyte for cAMP and 3 ,5 -cyclic guanosine-13 C, 15 N 2 monophosphate ( 13 C 15 N 2 -cGMP) as a surrogate analyte for cGMP. 3 ,5 -cyclic inosine monophosphate (cIMP) was selected as the internal standard (IS) due to its similarity to the target analytes and absence in blank matrix or study samples.
Material and methods

Reagents and animals
3 ,5 -cyclic adenosine-13 C 5 monophosphate ( 13 C 5 -cAMP) and 3 ,5 -cyclic guanosine-13 C, 15 N 2 monophosphate ( 13 C 15 N 2 -cGMP) were obtained from Toronto Research Chemicals, Inc. (North York, ON, Canada). 3 ,5 -cyclic adenosine monophosphate (cAMP) sodium salt monohydrate, 3 ,5 -cyclic guanosine monophosphate (cGMP) and 3 ,5 -cyclic inosine monophosphate (cIMP) sodium salt were obtained from Sigma-Aldrich (MO, USA); 2 ,3 -cyclic guanosine monophosphate (2 ,3 -cGMP) and 2 ,3 -cyclic adenosine monophosphate (2 ,3 -cAMP) were obtained from BioLog Life Science Institute (Breman, Gemany). Formic acid (∼98%, FA), perchloric acid (70%, PCA), dimethyl sulfoxide (≥99.9%, DMSO) and acetonitrile were purchased from Sigma-Aldrich (MO, USA). Male Sprague-Dawley rat brain was obtained from Bioreclamation IVT (Westbury, NY, USA).
Rat brain homogenate preparation
Male CD rats (200-250 g) rats (Charles River Laboratories; Hollister, CA) were group housed under standard vivarium conditions on a 12-h light-dark cycle with food and water available ad libitum. Animals were handled and cared for according to Dart NeuroScience Institutional Animal Care and Use Committee (IACUC) protocol. The animals were acclimated for at least 48 h prior to dosing. Surrogate analytes, 13 C 5 -cAMP and 13 C 15 N 2 -cGMP, stock solutions were prepared individually in methanol at a concentration of 0.500 mg/mL. Internal standard (cIMP) stock solution was prepared in DMSO at a concentration of 0.500 mg/mL. Stock solutions were stored at −20 • C when not in use.
Calibration curve, QCs and study sample preparation
Blank brain homogenate is prepared by combining a four-fold excess of 0.4 M PCA to frozen brain tissue. Samples containing the target analytes are also prepared by combining a four-fold excess of 0.4 M PCA to frozen brain tissue and therefore require application of a dilution factor of 5 in order to calculate the concentration of analytes in the intact tissue before homogenization. Calibration curves and QC samples containing both 13 C 5 -cAMP and 13 C 15 N 2 -cGMP were prepared by the addition of spiking solutions into rat brain homogenate. The final calibration curve concentrations were 5, 10, 20, 50, 100, 200, 500, 1000 and 2000 ng/g, while the QC sample final concentrations were 15, 300, 800 and 1600 ng/g. The calibration curves were freshly prepared in duplicate on the day of analysis. Aliquots (50-L) of fresh rat brain sample homogenate, blank brain homogenate, calibration standards or QCs were transferred to 96 well plates (1. 
LC-MS/MS conditions
Chromatographic separation was performed using a Waters Atlantis dc18, 3 , 3.0 × 100 mm column (Waters, Milford, MA) maintained at 40 • C. Mobile Phase A consisted of water with 0.1% formic acid and mobile Phase B consisted of acetonitrile with 0.1% formic acid, delivered with Shimadzu Prominence LC-30AD pumps at a total flow rate of 1.2 mL/min. The gradient began at 2% B and was ramped from 2 to 8% B from 0.10 to 1.7 min and held at 8% B for 0.2 min, then increased from 8 to 95% B at 2.2 min and held for 0.5 min, finally returning to 2% B at 2.77 min and held until 4 min for re-equilibration. The column was interfaced to an AB SCIEX 5500 QTRAP MS/MS system (Foster City, CA, USA) using a Turbo Spray source operated in negative ionization mode. The data was acquired using Analyst software (v1.6.2) and processed with MultiQuant (v3.0.2) companion software (Applied Biosystems/MDS Sciex, Canada).
The multiple reaction monitoring (MRM) transitions (m/z; negative mode) for 3 ,5 -cAMP and its surrogate analyte 13 C 5 -3 ,5 -cAMP were 328.0/134.1 and 333.0/134.0, respectively, and for 3 ,5 -cGMP and its surrogate analyte 13 C 15 N 2 -3 ,5 -cGMP were 343.9/150.0 and 347.0/153.0, respectively. The MRM for potential endogenous interferences, 2 3 -cAMP and 2 3 -cGMP, is the same as their respective 3 5 isomers. The MRM transition for the internal standard cIMP was 328.9/135.1. The proposed fragmentation of the analytes is shown in Fig. 1 . The source interface conditions included a source temperature of 500 • C, curtain gas pressure of 40 psi, a nebulizing gas (GS1) pressure of 45 psi and a heating gas (GS2) pressure of 45 psi. The IonSpray voltage (IS) was set at −4500 V. The detailed MRM transition and instrument optimization conditions are listed in Table 1s , while a sample chromatogram is presented in Fig. 2 .
Parallelism testing
A parallelism assessment was performed to determine how accurately the surrogate analyte (i.e. 13 C 5 -cAMP and 13 C 15 N 2 -cGMP) approach is for quantification of varying concentrations of endogenous cAMP or cGMP present in the biological matrix. In this experiment, six replicates of rat brain homogenate spiked with solvent-only or spiked with authentic (i.e. non-isotopically labeled analyte cAMP and cGMP) were added at four concentrations (15, 300, 800 and 1600 mg/mL) and compared following sample preparation and surrogate analyte LC-MS/MS analysis. The concentration of the authentic analyte QCs is equal to the measured authentic analyte concentration minus the endogenous authentic analyte concentration which was determined from the non-spiked rat brain homogenate.
Method suitability assessment
This method was qualified following recommendations given in the FDA Guidance for Industry-Bioanalytical Method Validation (2013) [26] . Linearity was evaluated in rat brain homogenate over the range of 5-2000 ng/g and the lower limit of quantification (LLOQ) was determined using six different LLOQ QC samples (5 ng/g). Carryover was evaluated by injecting the upper limit of quantification (ULOQ) sample followed by a matrix blank. Selectivity (including interference and matrix effect) was determined in six lots of rat brain. Interference was evaluated by comparing the LC-MS/MS response of the analyte in the LLOQ, blank and the double blank samples. Matrix effect was evaluated at five QC concentrations by comparing post-extraction spiked blank matrix and neat solution. Selectivity was determined by comparing the chromatographic separation of 3 ,5 cyclic nucleotides with their endogenous isomers, 2 ,3 cyclic nucleotides. Accuracy and precision were determined in three separate analytical runs, each containing 6 QC sample replicates at five concentrations covering the calibration curve range. Recovery was evaluated by comparing the analyte to IS peak area ratio of the pre-extraction spiked samples to corresponding post-extraction spiked samples.
Stability
The cNT surrogate analyte stock solutions (0.5 mg/mL in methanol) were evaluated under ambient conditions for at least 6 h at room temperature (RT), and for up to at least 490 days when stored at −20 • C.
To evaluate the stability of 13 C 5 -cAMP and 13 C 15 N 2 -cGMP in 0.4 M PCA processed rat brain homogenates, freeze-thaw stability, bench top stability and short term stability were performed using six replicates of low, medium, and high rat brain homogenate QC samples. Freeze-thaw stability was performed over five cycles with thawing at room temperature and refreezing at −80 • C for at least 12 h. Bench top stability was performed at room temperature for 24 h. Short term frozen stability was performed by storage at −80 • C for 2 weeks.
Post-extraction stability (i.e. processed sample stability and auto-sampler stability) was also evaluated for 13 C 5 -cAMP and 13 C 15 N 2 -cGMP. For the processed sample stability test, processed QC samples were stored at 4 • C for 24 h and analyzed using freshly prepared duplicate calibration curves. For the auto-sampler stability test, QC samples were reinjected after storage in the autosampler at 10 • C for 24 h.
Analyte to surrogate analyte response factor
For a robust surrogate analyte based LC-MS/MS bioanalytical method, the MRM response of the surrogate analyte should be comparable to that of the authentic analyte, otherwise a correction factor should be applied. Accordingly, the surrogate to endogenous analyte response factors were determined by individually injecting a neat solution (5 ng/g) of each surrogate analyte ( 13 C 5 -cAMP and 13 C 15 N 2 -cGMP) as well as the authentic analyte (cAMP and cGMP, respectively) in the presence of internal standard (cIMP, 50 ng/g) into LC-MS/MS. The mean peak area ratio (analyte:IS) of the surrogate analyte was compared to mean peak area ratio of the corresponding authentic analyte. If the response factor is greater than 5%, the response factor will be applied for the quantification of cAMP and/or cGMP using surrogate analyte calibration curve.
2.9. cAMP and cGMP baseline levels in microwave fixed rat brain tissue and commercially obtained rat brain tissue
Six male Sprague-Dawley (CD) rats weighing approximately 250 g were euthanized by focused microwave irradiation of the brain following procedures described in Section 2.2. The brains were removed and individual rat brain homogenates were prepared in 0.4 M PCA. Individual brain homogenates were similarly prepared from six commercially obtained male CD rat brains (BioreclamationIVT, Westbury, NY). Brain homogenates were processed following procedures described in Section 2.3. cAMP and cGMP baseline levels were analyzed by LC-MS/MS.
Results
LC-MS/MS method suitability assessment
3.1.1. Linearity and lower limit of quantification Calibration standards containing both 13 C 5 -cAMP and 13 C 15 N 2 -cGMP (minimum of eight concentrations) were prepared in rat brain homogenate at concentration levels between 5.00 and 2000 ng/g and analyzed by LC-MS/MS following the method in Section 2.4. Calibration curves of 13 C 5 -cAMP and 13 C 15 N 2 -cGMP were generated by linear regression of peak area ratio (analyte/IS) versus applied concentration using a 1/x 2 weighting. At least 75% of the calibration standards were within 15% of their nominal concentrations [26] . The correlation coefficients from 6 independent curves were ≥ 0.996 for both analytes.
The lower limit of quantification (LLOQ) was 5 ng/g for both 13 C 5 -cAMP and 13 C 15 N 2 -cGMP. The signal noise ratio at this concentration, determined in 6 replicates of the LLOQ was ≥38.0 and ≥21.8 respectively for 13 C 5 -cAMP and 13 C 15 N 2 -cGMP. The representative chromatograms of 13 C 5 -cAMP and 13 C 15 N 2 -cGMP at LLOQ (5 ng/g) and IS are shown in Fig. 1s. 
Parallelism assessment
Surrogate analyte ( 13 C 5 -cAMP/ 13 C 15 N 2 -cGMP) calibration curve and QC samples were used to determine the endogenous cAMP and cGMP levels in the rat brain homogenates. The mean measured endogenous cAMP level from 6 rat brains was 39.4 ± 0.8 ng/g, and cGMP was below qualification level (BQL) (< 5 ng/g) in 5 x diluted brain homogenates made from commercially obtained rat brains. The same rat brain matrix was used to make four levels of cAMP and cGMP QCs (n = 6 each level) by spiking in cAMP and cGMP stock solution. The nominal concentrations of cAMP and cGMP in each QC sample was equal to the endogenous level plus the spiked concentration. The CV% at each QC concentration was within 3.4% and 4.8% for cAMP and cGMP respectively. The mean percent of deviation (Dev%) from nominal was no greater than 7.0% and 10.5% for cAMP and cGMP respectively ( Table 1) . The precision and the accuracy of the calculated authentic analyte QCs were typically within 15%.
Carryover
The observed carryover after injecting the ULOQ samples followed by a matrix blank was no greater than 1.5% of LLOQ for 13 C 5 -cAMP, 0.7% of LLOQ for 13 C 15 N 2 -cGMP and 0% of the internal standard response. Test article carryover was ≤ 20% of the LLOQ and internal standard carryover was ≤ 5% of the internal standard response (Table 2s ).
Response factor
The MRM response of the authentic analyte was compared to the MRM of the surrogate analyte to evaluate response at the final concentration of 5 ng/g in the presence of cIMP (IS) 50 ng/g. The average response factors of the 6 runs were 113% (CV% = 3.4%) for cAMP to 13 C 5 -cAMP, and 123% (CV% = 3.5%) for cGMP to 13 C 15 N 2 -cGMP respectively. These response factors were applied for cAMP and cGMP concentration calculations.
Selectivity and specificity
Selectivity (interference) was shown by comparing the LLOQ QC samples to the zero concentration samples (single blank; rat brain blank +IS) and the blank samples (double blank; rat brain blank without IS). No interference peak was observed for 13 C 5 -cAMP, 13 C 15 N 2 -cGMP and cIMP in triplicate analyses of six lots of single and double blank rat brain (Fig. 1s) . Specificity was shown by the separation of 3 ,5 cyclic nucleotides to their naturally occurring isomer, 2 ,3 cyclic nucleotide at a concentration of 50 ng/g. Naturally occurring 2 ,3 isomers of these cyclic nucleotides were well separated from the 3 ,5 cyclic nucleotide in the 4 min LC chromatogram developed (Fig. 2) . Therefore, although those isomers share the same multiple reaction monitoring (MRM) transitions with the 3 ,5 cyclic nucleotides of interest, there is no interference with 3 ,5 cyclic nucleotide detection. 3.1.6. Matrix effect Matrix effect was determined in homogenates prepared from six lots of commercially obtained rat brain matrix. Three postspiked replicates of each lot of brain matrix at 0, 5, 15, 300, 800 and 1600 ng/g and three post-spiked replicate samples without brain matrix at 0, 5, 15, 300, 800 and 1600 ng/g along with 50 ng/g IS across all the samples were analyzed to calculate a matrix factor for 13 C 5 -cAMP, 13 C 15 N 2 -cGMP and IS. The IS normalized matrix effect was calculated by dividing the mean peak area ratio of the spiked samples with brain matrix by the mean peak area ratio of the spiked samples without brain matrix. The IS normalized matrix factor is listed in Table 3s . The matrix effect for the IS was determined by dividing the mean peak area response of the 0 ng/g spiked samples with brain matrix by the mean peak area response of the 0 ng/g spiked samples without brain matrix. The matrix factor ranged from 0.99 to 1.00 for 13 C 5 -cAMP and 0.97 to 1.00 for 13 C 15 N 2 -cGMP across all concentration levels tested. The matrix factor was 0.97 for IS at a concentration of 50 ng/g. The CV% at each concentration level was ≤ 4.2, 4.6 and 1.3 for 13 C 5 -cAMP, 13 C 15 N 2 -cGMP and IS, respectively, indicating the method has acceptable matrix effects.
Accuracy and precision
Six replicates of QC samples at concentrations of 5, 15, 300, 800 and 1600 ng/g representing lower limit of quantification quality control sample, as well as low, mid and high quality control samples were assessed for accuracy and precision. Three runs were assessed and statistics were determined from three analytical runs. The accuracy and precision results are listed in Table 2 . The intra-run precision (CV%) was within 6.6% and 7.4%; the inter-run precision (CV%) was within 8.5% and 5.8% for 13 C 5 -cAMP and 13 C 15 N 2 -cGMP, respectively. Compared with nominal concentrations, the intraassay accuracy (Dev%) was within 11.9% and 10.3%; the inter-run accuracy (Dev%) was within 6.6% and 5.5% of respective 13 C 5 -cAMP and 13 C 15 N 2 -cGMP nominal concentrations. All samples analyzed were within the required criteria.
Recovery
Six replicates of QC samples at 5, 15, 300, 800 and 1600 ng/g were spiked into rat brain homogenate pre-and post-sample preparation to determine sample processing recovery. The sample processing recovery was calculated by dividing the mean pre- extraction spiked values by the mean post-extraction spiked values and the results were expressed as a percentage. The recoveries of 13 C 5 -cAMP from rat brain homogenates were 90.4%, 86.5%, 89.7%, 88.6% and 86.6%, respectively. The recoveries of 13 C 15 N 2 -cGMP from rat brain homogenate were 100.5%, 99.7%, 103.0%, 101.6% and 98.9%, respectively (Table 3) .
3.1.9. Stability Both 13 C 5 -cAMP and 13 C 15 N 2 -cGMP stock solutions (0.5 mg/mL) in methanol were stable at room temperature for 6 h showing less than 2.5% deviation (Dev%) from stocks stored at 4 • C (Table 4) . Stock solutions of 13 C 5 -cAMP and 13 C 15 N 2 -cGMP in methanol were stable at −20 • C for 18 months showing less than 3% deviation from time 0 (data not shown).
The stability of 13 C 5 -cAMP and 13 C 15 N 2 -cGMP in rat brain homogenate was evaluated for room temperature stability (room temperature, 24 h), freeze-thaw stability (5 freeze-thaw cycles, −80 • C) and long-term stability (-80 • C, 2 weeks). The results showed that both 13 C 5 -cAMP and 13 C 15 N 2 -cGMP were stable in rat brain homogenate on the bench-top at room temperature for 24 h before extraction with accuracy (shown in Dev%) within 6.3% and 12.5% of the respective 13 C 5 -cAMP and 13 C 15 N 2 -cGMP nominal concentrations; stable after 5 freeze-thaw cycles (-80 • C) with Dev% within 10.3% and 8.9% of the respective 13 C 5 -cAMP and 13 C 15 N 2 -cGMP nominal concentrations; and stable after frozen storage at −80 • C for 2 weeks with Dev% within 12.8% and 5.4% of the respective 13 C 5 -cAMP and 13 C 15 N 2 -cGMP nominal concentrations ( Table 4 ).
The post-processed samples were stable in the auto-sampler (10 • C) for 24 h (reinjection integrity). The accuracy, as shown in Dev%, was within 9.3% and 19.2% of the respective 13 C 5 -cAMP and 13 C 15 N 2 -cGMP nominal concentrations. The post-processed samples were stable at 4 • C for 24 h against fresh prepared calibration curves (processed sample stability). The Dev% was within 12.9% and 11.9% of the respective 13 C 5 -cAMP and 13 C 15 N 2 -cGMP nominal concentrations (Table 4) .
3.1.10. cNT baseline levels in microwave fixed rat brain and commercial rat brain
The cAMP or cGMP baseline levels in rat brain provide useful information for subsequent bio-marker studies. We studied the effect of rat brain harvesting on the levels of endogenous cAMP and cGMP. Endogenous cAMP and cGMP levels were evaluated in microwave-fixed rat brain (n = 6) and commercially obtained rat brain (n = 6) using the described qualified assay. In microwave fixed rat brains, the cAMP baseline levels were approximately 400 ± 38 ng/g (1.22 ± 0.12 nM/g) and the cGMP baseline levels were approximately 27 ± 2.5 ng/g (0.0753 ± 0.0072 nM/g) (Fig. 3) , which is consistent with reported literature values [27] . In commercially obtained rat brains, the cAMP levels were 241 ± 32 ng/g (0.733 ± 0.097 nM/g) and cGMP levels were BQL. Generally, the cAMP and cGMP levels in the commercially obtained rat brains are lower than microwave fixed rat brains. In the non-microwave fixed brain samples like the commercially obtained rat brain samples, PDEs are active and therefore cAMP and cGMP levels decrease during sample handling. The traditional approach to minimize cyclic nucleotide degradation during tissue harvesting has been to rapidly freeze samples in liquid nitrogen or carbon dioxide ice [16, 17] . However this doesn't avoid potential degrading that occurs from the time between euthanization and tissue freezing. In this report, microwave euthanasia was used in sample collection. Microwave fixation deactivates proteins, including PDEs, within a second of irradiation [28] . To further stabilize samples against any remaining active PDEs, microwave fixed brain samples were prepared by rapid homogenization in 0.4 M perchloric acid. In the microwave fixed rat brains, cAMP and cGMP levels are stabilized [29] allowing for more accurate quantitation of cNTs.
Conclusion
A medium-throughput LC-MS/MS assay was developed and qualified according to FDA recommendations to simultaneously quantify cAMP and cGMP levels in rat brain. In this assay, 13 C 5 -cAMP was used as the surrogate analyte of cAMP while 13 C 15 N 2 -cGMP was used as the surrogate analyte of cGMP. The LC-MS/MS responses between the surrogate analyte and the authentic analyte were 1.13 for cAMP and 1.23 for cGMP. Accordingly, respective response factors of 1.13 and 1.23 were applied when determining the surrogate analyte derived cAMP or cGMP concentrations in rat brain. The method was found to have sufficient accuracy, precision and an extended linear dynamic range for use in assessing these cNTs in pharmocodynamic or biomarker studies. The sample processing recovery was ≥86.5% and 99.7% for 13 C 5 -cAMP and 13 C 15 N 2 -cGMP, respectively. In addition, a parallelism assessment showed the surrogate analyte curve accurately quantifies the endogenous cNTs over a range of concentrations. This assay was demonstrated to be accurate, sensitive and robust with good throughput. It is suitable for the bioanalysis of endogenous cAMP and cGMP levels in rat brain obtained from preclinical studies.
